Cervical carcinoma (squamous predominant + adeno) · line 1 · Pembrolizumab + paclitaxel + carboplatin ± bevacizumab (cervical cancer, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-PEMBRO-PACLI-CARBO-BEV-CERVICAL`

ID	`IND-CERVICAL-METASTATIC-1L-PEMBRO-CHEMO-BEV`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-CERVICAL`
Sources	`SRC-ESMO-CERVICAL-2024` `SRC-NCCN-CERVICAL-2025`

Notes

STUB — requires clinical co-lead signoff. Closes Phase A audit gap for DIS-CERVICAL L1-metastatic indication (the existing IND-CERVICAL-LOCALLY-ADVANCED-CRT only covers locally-advanced curative CRT, not the metastatic / recurrent setting). Regimen entity not yet created (REG-PEMBRO-PACLI-CARBO-BEV would be the canonical ID).

Used By

Actionability

BMA-PDL1-CPS-CERVICAL - PD-L1 CPS ≥1 is required for pembrolizumab in persistent/recurrent/metastatic cervical ca...

Algorithms

ALGO-CERVICAL-METASTATIC-1L - ALGO-CERVICAL-METASTATIC-1L